Mylan: PharmaVitae Generics Profile

Table of Contents

• CHAPTER 1 EXECUTIVE SUMMARY
  • Key findings
  • Historical ethical sales performance
  • Therapeutic focus
  • Branded and generic drug outlook, 2006-12
  • Generic drug launch history
  • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
• CHAPTER 2 CORPORATE HISTORY
  • Key findings
  • Background
  • Key corporate developments
    • Mylan
    • Merck Generics
  • M&A history
    • Matrix acquisition
    • Merck Generics acquisition
    • M&A strategy
    • Deals and alliances
  • Current corporate structure
  • Current management team
• CHAPTER 3 HISTORICAL PERFORMANCE
  • Key findings
  • Introduction
  • Revenue and growth rate analysis, 2001-06
    • Revenue and growth rate versus generic peer set
  • Product analysis, 2002-06
    • Growth drivers
    • Growth resistors
  • Operating revenue and cost analysis, 2002-06
    • Operating revenue/cost analysis
• CHAPTER 4 BRAND FORECAST PERFORMANCE
  • Key findings
  • Overview
  • Overview
    • Branded growth drivers
      • Mentax
      • Maxzide
      • Avita, Clorpres and Eldepryl
      • Curosurf (poractant alpha)
      • Dey' s respiratory franchize
    • Branded drug launch and expiry outlook
    • Branded drug development programs
      • Apokyn (apomorphine)
      • ENSAM (transdermal selegiline)
      • Nebivolol (nebilet)
• CHAPTER 5 KEY PRODUCTS AND COMPETITORS
  • Key findings
  • Overview
  • Therapy area focus, 2002-06
    • Generic portfolio
    • Generic and biosimilar products
      • Fentanyl
      • Omeprazole
      • Nifedipine
      • Epipen (autoinjectable epinephrine)
      • Amnesteem (tretinoin)
      • Generic drug launches in 2006
  • Biosimilar outlook
• CHAPTER 6 APPENDIX
  • IMS versus company-reported data reconciliation
  • References
  • Abbreviations
  • Exchange rates
  • List of Tables
    • Table 1: Mylan' s product licensing agreements, 2000-06
    • Table 2: Mylan' s corporate executive committee
    • Table 3: Generic peer set overview, 2006
    • Table 4: Mylan' s operating revenue/cost analysis ($m), FY 2002-06
    • Table 5: Mylan' s operating cost ratio analysis (% of total revenues), FY 2002-06
    • Table 6: Dey' s respiratory franchize forecast sales 2006-12, 7 major markets ($m)
    • Table 7: Key product overview for Mylan combined with Merck Generics, 7 major market sales ($m), 2006
    • Table 8: Generic drugs launched by Mylan and Merck Generics, 2006
    • Table 9: Disclosed potential first-to-file opportunities for Mylan, 2007
    • Table 10: Exchange rates, 2006
  • List of Figures
    • Figure 1: Historical ethical (generic and brand) global sales performance for Mylan, combined with those of Merck Generics, and the generic pharma peer set (% CAGR), 2002-06
    • Figure 2: Mylan and Merck Generics combined generic therapeutic focus versus generic pharma peer set (%), 2006
    • Figure 3: Mylan' s branded and generic drug forecast ($m), 2006-12
    • Figure 4: Percentage revenues attributed to generics launched in the US by Mylan, combined with those of Merck Generics, and the generic peer set, 2002-06
    • Figure 5: Mylan' s ANDA submission history, 2002-07
    • Figure 6: Mylan - SWOT analysis, 2007
    • Figure 7: Mylan' s M&A history, 2001-06
    • Figure 8: Mylan' s acquisition of Matrix, 2006
    • Figure 9: Merck Generic' s global positioning, 2007
    • Figure 10: Mylan' s corporate structure, 2007
    • Figure 11: Mylan' s global ethical sales revenue and growth rate ($m), FY 2001-06
    • Figure 12: Mylan' s total global ethical revenue and growth rate compared to generic peer set, 2001-06
    • Figure 13: Mylan' s growth drivers/resistors of historical revenue performance ($m), 2002-06
    • Figure 14: Mylan- operating revenue/cost analysis ($m), FY 2002-06
    • Figure 15: Mylan' s operating cost ratio analysis (% of total revenues), FY 2002-06
    • Figure 16: Mylan' s operating cost ratio versus peer set (%), FY 2006
    • Figure 17: Mylan and Merck Generic' s combined branded drug sales, 2002-06
    • Figure 18: Launch, Core and Expiry Portfolio for Mylan' s branded franchise, combined with that of Merck Generics, 7 major markets, 2006-12
    • Figure 19: Mylan' s top 6 products, seven major market sales ($m), 2006
    • Figure 20: Mylan' s generic sales by therapeutic class, combined with those of Merck Generics, 2006
    • Figure 21: IMS versus company-reported ethical sales discrepancy ($m), 2006